Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk
| Autor: | Theano Tatsi, Anna Kalogera-Fountzila, Lemonia Skoura, Vasiliki Tsavdaridou, Eleni Polyzoidou, Dimitrios Parissis, Eleni Grigoriadou, Virginia Giantzi, Panagiotis Ioannidis, Theodoros Karapanayotides, Roza Lagoudaki, Nikolaos Grigoriadis, Ioannis Nikolaidis, Theodora Afrantou, Pamela Melo, Marina Boziki, Sofia Zoidou, Georgios C. Papadopoulos, Evdoxia Gounari, Nikolaos Mandoras, Christos Bakirtzis, Sygkliti-Henrietta Pelidou |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
CD4-Positive T-Lymphocytes Male 0301 basic medicine Lymphocyte 03 medical and health sciences Multiple Sclerosis Relapsing-Remitting 0302 clinical medicine Natalizumab Risk Factors parasitic diseases medicine Humans Immunologic Factors In patient L-Selectin biology business.industry Multiple sclerosis Progressive multifocal leukoencephalopathy Functional implication Leukoencephalopathy Progressive Multifocal Brain General Medicine Middle Aged medicine.disease 030104 developmental biology medicine.anatomical_structure Neurology Immunology biology.protein Female L-selectin Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Neurological Research. 42:209-221 |
| ISSN: | 1743-1328 0161-6412 |
| DOI: | 10.1080/01616412.2020.1722913 |
| Popis: | Objectives: Natalizumab (NTZ), a treatment indicated for patients with highly active Relapsing – Remitting Multiple Sclerosis (RRMS), is known to induce increased relative frequency of lymphocytes. Progressive Multifocal Leukoencephalitis (PML) is a rare but serious adverse event related to NTZ. Moreover, reduced L-selectin (CD62L) expression in T-cells in cryopreserved samples of patients with RRMS under NTZ has been proposed as a biomarker of pre-PML state. We explore the association between L-selectin expression in T-cells and hematological parameters in freshly processed samples of patients with RRMS under NTZ. Methods: We studied L-selectin expression in patients with: RRMS under NTZ (n=34), fingolimod (FTY, n=14), interferon-beta (IFNβ, n=22), glatiramer acetate (GA, N=17); in 9 patients with secondary progressive (SP) MS and in 6 healthy controls. Twenty-two patients under NTZ and 6 patients under FTY were followed for 18 months. One NTZ-treated patient developed PML during the study. Results: Patients under NTZ exhibited increased relative frequency of lymphocytes (40.02±1.45) compared to patients under first–line treatment (30.57±1.68, pDiscussion: We hereby provide mechanistic insight in a possible pathway implicated in NTZ-related PML risk. These results further underline the need for thorough validation of L-selectin expression in T-cells as a potential pre-PML biomarker. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|